Quick Answer
REGENERON PHARMACEUTICALS, INC. reported Stockholders Equity of $31.26 billion for the year ending 2025.
- REGENERON PHARMACEUTICALS, INC. showed an increase of +6.5% in Stockholders Equity from 2024 to 2025.
- This data is from REGENERON PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 4, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $2.21 billion | Q2 2014: $2.37 billion | Q3 2014: $2.55 billion | Q1 2015: $2.97 billion | Q2 2015: $3.34 billion | Q3 2015: $3.30 billion | Q1 2016: $3.77 billion | Q2 2016: $4.08 billion | Q3 2016: $4.49 billion | Q1 2017: $4.87 billion | Q2 2017: $5.52 billion | Q3 2017: $6.05 billion | Q1 2018: $6.57 billion | Q2 2018: $7.19 billion | Q3 2018: $7.87 billion | Q1 2019: $9.44 billion | Q2 2019: $9.76 billion | Q3 2019: $10.50 billion | Q1 2020: $12.13 billion | Q2 2020: $9.06 billion | Q3 2020: $10.13 billion | Q1 2021: $11.98 billion | Q2 2021: $15.13 billion | Q3 2021: $17.26 billion | Q1 2022: $19.91 billion | Q2 2022: $20.69 billion | Q3 2022: $21.44 billion | Q1 2023: $23.50 billion | Q2 2023: $24.02 billion | Q3 2023: $24.90 billion | Q1 2024: $26.99 billion | Q2 2024: $28.21 billion | Q3 2024: $29.33 billion | Q1 2025: $29.39 billion | Q2 2025: $29.94 billion | Q3 2025: $30.96 billion.
- Over the full 14 years of available data (2012 to 2025), REGENERON PHARMACEUTICALS, INC.'s Stockholders Equity has grown by 2,387.4%.
- Historical annual values: Fiscal year 2025: $31.26 billion | Fiscal year 2024: $29.35 billion | Fiscal year 2023: $25.97 billion | Fiscal year 2022: $22.66 billion | Fiscal year 2021: $18.77 billion | Fiscal year 2020: $11.03 billion | Fiscal year 2019: $11.09 billion | Fiscal year 2018: $8.76 billion | Fiscal year 2017: $6.14 billion | Fiscal year 2016: $4.45 billion | Fiscal year 2015: $3.65 billion | Fiscal year 2014: $2.55 billion | Fiscal year 2013: $1.96 billion | Fiscal year 2012: $1.26 billion.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: